I wonder what does this latest news means for ANP (if anything?)
United States Patent and Trademark Office (USPTO) rules in favor of Santaris Pharma A/S in patent re-examination cases for two key Santaris Pharma A/S "Imanishi" patents
- Patents cover the 2'-4' bicyclic nucleotides known as LNA (Locked Nucleic Acid) or BNA (Bicyclic Nucleic Acid) chemistry that Santaris Pharma A/S has successfully developed to generate effective RNA-targeted therapies for a wide range of diseases
- Santaris Pharma A/S LNA Drug Platform is rapidly becoming the technology-of-choice for partners interested in developing RNA-targeted medicines for unmet medical needs
isis loses patent challenge
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.008(8.25%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 9.8¢ | 11.0¢ | 9.8¢ | $360.4K | 3.457M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 248759 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |